Sentence examples for candidate pharmaceuticals from inspiring English sources

Candidate pharmaceuticals and medical devices, for example, must wend their way through a complicated regulatory system to approval, often propelled by billions of dollars in investment.

Tetracyclines, by virtue of their non-antimicrobial pro-anabolic and anti-catabolic properties, are excellent candidate pharmaceuticals to simultaneously treat these local and systemic disorders.

Despite the great potential of ATR inhibitors, there is a paucity of potent, selective candidate pharmaceuticals due to of the difficulties in obtaining active ATR protein to support drug discovery efforts.

Given a novel candidate pharmaceutical agent, a corresponding prospective antidote might be developed on the basis of specific ligand-receptor interactions.

As anticipated in the Concept Paper, the guidance is intended 'to facilitate a directed exploration of the physiology, pharmacology and/or pharmacokinetics of one or more candidate pharmaceutical products in humans' in order 'to optimise the selection of safer, more effective therapeutics for further development and ultimately make them available to patients sooner'.

Furthermore, several therapeutic candidate protein pharmaceuticals purified using IMAC are currently in clinical studies [ 34– 34].

Cellulose nanofibers (CNF) are an excipient candidate in pharmaceutical formulations that could be used to easily optimize drug delivery rates.

Based on hypoxia-induced up regulation and proposed scavenging of reactive oxygen species Cytoglobin was suggested as a candidate for pharmaceutical stroke treatment.

Glucagon-like peptide-1 (GLP-1) is an interesting candidate for pharmaceutical use in cases of diabetes mellitus type 1 and 2 since it controls the early insulin response to nutrient ingestion of glucose.

The literature has been extensively surveyed in order to identify a series of candidate Active Pharmaceutical Ingredients (API) for flowsheet synthesis, process modelling and mass balance simulation toward rapid assessment of CPM potential.

Vaidy Ganapathy is a doctoral candidate in Pharmaceutical economics & policy at USC who conducted the analyses and prepared a first draft of this manuscript.